Literature DB >> 7877990

Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression.

Y Dai1, E M Schwarz, D Gu, W W Zhang, N Sarvetnick, I M Verma.   

Abstract

Recombinant adenoviruses containing the canine factor IX (FIX) cDNA were directly introduced in the hind leg muscle of mice. We show that (i) in nude mice, high expression (1-5 micrograms/ml in plasma) of FIX protein can be detected for > 300 days; (ii) in contrast, expression of FIX protein was transient (7-10 days) in normal mice; (iii) CD8+ lymphocytes could be detected within 3 days in the infected muscle tissue; (iv) use of beta 2-microglobulin and immunoglobulin M heavy chain "knockout" mice showed that lack of sustained expression of FIX protein is due to cell-mediated and humoral immune responses; (v) normal mice, once infected with recombinant adenovirus, could not be reinfected efficiently for at least 30 days due to neutralizing viral antibodies; and, finally, (vi) using immunosuppressive drugs, some normal mice can be tolerized to produce and secrete FIX protein for > 5 months. We conclude that currently available adenoviral vectors have serious limitations for use for long-term gene therapy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7877990      PMCID: PMC42527          DOI: 10.1073/pnas.92.5.1401

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  23 in total

1.  Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver.

Authors:  J F Engelhardt; X Ye; B Doranz; J M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-21       Impact factor: 11.205

2.  Genetic analysis of adenoviruses.

Authors:  T Shenk; J Williams
Journal:  Curr Top Microbiol Immunol       Date:  1984       Impact factor: 4.291

3.  Adenovirus as an expression vector in muscle cells in vivo.

Authors:  B Quantin; L D Perricaudet; S Tajbakhsh; J L Mandel
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

4.  Adenovirus-mediated transfer of a recombinant alpha 1-antitrypsin gene to the lung epithelium in vivo.

Authors:  M A Rosenfeld; W Siegfried; K Yoshimura; K Yoneyama; M Fukayama; L E Stier; P K Pääkkö; P Gilardi; L D Stratford-Perricaudet; M Perricaudet
Journal:  Science       Date:  1991-04-19       Impact factor: 47.728

5.  Evaluation of the transfer and expression in mice of an enzyme-encoding gene using a human adenovirus vector.

Authors:  L D Stratford-Perricaudet; M Levrero; J F Chasse; M Perricaudet; P Briand
Journal:  Hum Gene Ther       Date:  1990       Impact factor: 5.695

6.  Phenotypic correction of factor IX deficiency in skin fibroblasts of hemophilic dogs.

Authors:  J H Axelrod; M S Read; K M Brinkhous; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

7.  A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene.

Authors:  D Kitamura; J Roes; R Kühn; K Rajewsky
Journal:  Nature       Date:  1991-04-04       Impact factor: 49.962

8.  An alternative approach to somatic cell gene therapy.

Authors:  D St Louis; I M Verma
Journal:  Proc Natl Acad Sci U S A       Date:  1988-05       Impact factor: 11.205

9.  Inactivating the beta 2-microglobulin locus in mouse embryonic stem cells by homologous recombination.

Authors:  B H Koller; O Smithies
Journal:  Proc Natl Acad Sci U S A       Date:  1989-11       Impact factor: 11.205

Review 10.  Cytotoxic suppression of acquired factor VIII:C inhibitors.

Authors:  D Green
Journal:  Am J Med       Date:  1991-11-04       Impact factor: 4.965

View more
  127 in total

1.  Frequency and stability of chromosomal integration of adenovirus vectors.

Authors:  A Harui; S Suzuki; S Kochanek; K Mitani
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

2.  Nonmyeloablative immunosuppressive regimen prolongs In vivo persistence of gene-modified autologous T cells in a nonhuman primate model.

Authors:  C Berger; M L Huang; M Gough; P D Greenberg; S R Riddell; H P Kiem
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

3.  Improved production of gutted adenovirus in cells expressing adenovirus preterminal protein and DNA polymerase.

Authors:  D Hartigan-O'Connor; A Amalfitano; J S Chamberlain
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

4.  Implication of interfering antibody formation and apoptosis as two different mechanisms leading to variable duration of adenovirus-mediated transgene expression in immune-competent mice.

Authors:  D B Schowalter; C L Himeda; B L Winther; C B Wilson; M A Kay
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

5.  Chromosomal integration pattern of a helper-dependent minimal adenovirus vector with a selectable marker inserted into a 27.4-kilobase genomic stuffer.

Authors:  M Hillgenberg; H Tönnies; M Strauss
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

6.  Distinct roles of adenovirus vector-transduced dendritic cells, myoblasts, and endothelial cells in mediating an immune response against a transgene product.

Authors:  Stéphanie Mercier; Hanne Gahéry-Segard; Martine Monteil; Renée Lengagne; Jean-Gérard Guillet; Marc Eloit; Caroline Denesvre
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

7.  Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon.

Authors:  Hongju Wu; Igor Dmitriev; Elena Kashentseva; Toshiro Seki; Minghui Wang; David T Curiel
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

8.  Tumor necrosis factor alpha plays a central role in immune-mediated clearance of adenoviral vectors.

Authors:  K B Elkon; C C Liu; J G Gall; J Trevejo; M W Marino; K A Abrahamsen; X Song; J L Zhou; L J Old; R G Crystal; E Falck-Pedersen
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

9.  Immunological aspects of recombinant adeno-associated virus delivery to the mammalian brain.

Authors:  Mihail Y Mastakov; Kristin Baer; C Wymond Symes; Claudia B Leichtlein; Robert M Kotin; Matthew J During
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

10.  Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity.

Authors:  Ronald Vogels; David Zuijdgeest; Richard van Rijnsoever; Eric Hartkoorn; Irma Damen; Marie-Pierre de Béthune; Stefan Kostense; Germaine Penders; Niels Helmus; Wouter Koudstaal; Marco Cecchini; Antoinette Wetterwald; Mieke Sprangers; Angelique Lemckert; Olga Ophorst; Björn Koel; Michelle van Meerendonk; Paul Quax; Laura Panitti; Jos Grimbergen; Abraham Bout; Jaap Goudsmit; Menzo Havenga
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.